Clinical trial NCT03807440: DIA_CENTRAL:T2D Treatment Pattern in Central Europe
Official title: CORDIALLY® - CEE: Characteristics of Patients With Type 2 Diabetes Treated With Modern Antidiabetic Drugs. A Real World Data Collection of Patient Baseline Characteristics, Treatment Patterns and Comorbidities in Central Eastern European (CEE) Countries
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Diabetes Mellitus, Type 2
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2019-01-17
Enrollment: 4083
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients (18 years of age or older) with Type 2 Diabetes diagnosis, naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), DPP4i (Dipeptidyl-peptidase 4 inhibitor) or GLP1a (Glucagon-like peptide 1 agonist) at index date were chosen.

Brief summary: This is a non-interventional study using existing data including medical chart review.


Eligibility criteria: Inclusion Criteria:

1. Written informed consent prior to participation
2. Female and male patients age ≥ 18 years
3. Patients with T2D diagnosis
4. Patients who have been newly initiated (first ever use) with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) between September 2018 and December 2018 (study index date 1)
5. Patients have been naïve to treatment with empagliflozin or other Sodium Glucose Transporter 2 inhibitor (SGLT2i), Dipeptidyl-peptidase 4 inhibitor (DPP4i) or Glucagon-like peptide 1 agonist (GLP1a) at study index date 1

Exclusion Criteria:

1. Patients age \< 18 years
2. Patients with diagnosis of other types of diabetes than T2D
3. Patients who do not provide written consent to the terms of the study

Primary outcomes:
measure: Number of Patients in Each Category of First Prescription of a Respective Modern Type 2 Diabetes (T2D) Medication According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant T2D Medications at Study Index Date 1 According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients Initiated on a Modern Type 2 Diabetes (T2D) Medication Who Also Received Concomitant Cardiovascular Disease (CVD) and/or Chronic Kidney Disease (CKD) Medication at Study Index Date 1 According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Age According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Gender According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Body Mass Index (BMI) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Baseline Characteristic: Number of Patients in Each Category of Race According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Time Since Diagnosis of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for T2D: Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for Type 2 Diabetes (T2D): Percentage of Glycosylated Hemoglobin (HbA1c [%]) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Clinical Parameter Relevant for Type 2 Diabetes (T2D): Number of Patients in Each Category of Percentage of Glycosylated Hemoglobin (HbA1c) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: 10-year Risk for Fatal Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients Per Type of Medical Specialty of Other Physicians Involved in Treatment Decision According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
Secondary outcomes:
measure: Number of Patients With Any Type of Cardiovascular Disease (CVD)
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney Disease (CKD) by Physician's Assessment
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Documentation of Estimated Glomerular Filtration Rate (eGFR) / Urine Albumin Creatinine Ratio (UACR) Status
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney Disease (CKD) by Estimated Glomerular Filtration Rate (eGFR) and Urine Albumin Creatinine Ratio (UACR) Status
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of the Different Types of Cardiovascular Disease
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of the Different Types of Congestive Heart Failure (CHF) - Confirmed by Echocardiography
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Any Type of Cardiovascular Disease (CVD) and Without CVD According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney (CKD) (Patients for Whom CKD Was Reported as a Comorbidity) or Without CKD by Physician's Assessment According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney Disease (CKD) by eGFR and UACR Status According to Prescribing Specialist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Different Types of Cardiovascular Disease (CVD) According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Congestive Heart Failure (CHF) Confirmed by Echocardiography According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication From by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With or Without at Least One Cardiovascular Disease (CVD) Type According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney (CKD) or Without CKD by Physician's Assessment According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients With Chronic Kidney (CKD) and Without CKD by eGFR and UACR Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Employment Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Family Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Insurance Status According to Type 2 Diabetes (T2D) Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 1 (i.e. between September 2018 and December 2018).
measure: Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Status of Type 2 Diabetes (T2D) Medication at Index Date 2 According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication by Country
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to Type 2 Diabetes (T2D) Medication Initiated at Study Index Date 1
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Endocrinologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Diabetologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients in Each Category of Reason for Discontinuation of Type 2 Diabetes (T2D) Medication According to T2D Medication for the Patients Who Were Initiated on T2D Medication by Cardiologist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Number of Patients for Each Type of Physician Specialties Involved in Decision for T2D Therapy Discontinuation According to Prescribing Specialist
timeFrame: At study index date 2 (= one year ± 2 months after index date 1 (study index date 1 was between September 2018 and December 2018)).
measure: Time to Discontinuation of Type 2 Diabetes (T2D) Treatment According to Study Medication
timeFrame: From date of first prescription (study index date 1) to stop date of initial type 2 diabetes (T2D)) medication (documented at index date 2), up to 14 months..
Other outcomes:
Locations:
city: Byala
country: Bulgaria
facility: MHAT "Julia Verevska-Byala" EOOD, Center Nr.: 35903
city: Dimitrovgrad
country: Bulgaria
facility: MC "Diamedical 2013" OOD, Center Nr.: 35902
city: Dobrich
country: Bulgaria
facility: MBAL- Dobrich AD, Center Nr.: 35916
city: Dupnitsa
country: Bulgaria
facility: Dr. T. K. Bacheva - ASMP-IP-E EOOD, Center Nr.: 35904
city: Plovdiv
country: Bulgaria
facility: MHAT "Medline Clinic", Center Nr.: 35911
city: Plovdiv
country: Bulgaria
facility: MC Kuchuk Parij OOD, Center Nr.: 35906
city: Rakovski
country: Bulgaria
facility: MC Saint Elisaveta-Rakovski EOOD, Center Nr.: 35909
city: Razgrad
country: Bulgaria
facility: "Medical Center-Razgrad"OOD, Center Nr.: 35910
city: Russe
country: Bulgaria
facility: DCC 1 - Russe EOOD, Center Nr.: 35905
city: Sliven
country: Bulgaria
facility: MBAL "Hadzhi Dimitar" OOD, Center Nr.: 35915
city: Sofia
country: Bulgaria
facility: MC Polimed AD, Center Nr.: 35907
city: Sofia
country: Bulgaria
facility: MC Gina - LZ SIMP EOOD, Center Nr.: 35918
city: Sofia
country: Bulgaria
facility: MC "Vitaclinic" EOOD, Center Nr.: 35901
city: Sofia
country: Bulgaria
facility: MC Kalimat EOOD, Center Nr.: 35914
city: Varna
country: Bulgaria
facility: Acibadem City Clinic Medical Center Varna EOOD, Center Nr.: 35908
city: Beclav
country: Czechia
facility: Michal Brada, Center Nr.: 42001
city: Beroun
country: Czechia
facility: Dr. Kovaová, Center Nr.: 42069
city: Bilina
country: Czechia
facility: Practice Dr. Alice Sýkorová, Center Nr.: 42057
city: Broumov
country: Czechia
facility: MUDr. Alica Vesela, Center Nr.: 42030
city: Eské Budjovice
country: Czechia
facility: EUC Klinika eské Budjovice, Center Nr.: 42052
city: Eské Budjovice
country: Czechia
facility: Lékaský dm Géko, Center Nr.: 42059
city: Havíov
country: Czechia
facility: Barbara Buzová, Center Nr.: 42003
city: Havíov
country: Czechia
facility: Zaviatiová, Petra, Center Nr.: 42004
city: Hlušovice
country: Czechia
facility: Radana Syslová, Center Nr.: 42035
city: Hoovice
country: Czechia
facility: Pavel Kasík, Center Nr.: 42046
city: Humpolec
country: Czechia
facility: Practice Dr. Petr Maule, Center Nr.: 42054
city: Jihlava
country: Czechia
facility: Mediab Jihlava s.r.o., Center Nr.: 42066
city: Karlovy Vary
country: Czechia
facility: Practice MUDr. Gita Markofová, Center Nr.: 42053
city: Karviná - Staré Msto
country: Czechia
facility: Dr. Konená, Center Nr.: 42036
city: Karviná-Hranice
country: Czechia
facility: Practice Zdzislaw Wranka, Center Nr.: 42072
city: Kopivnice
country: Czechia
facility: Pavel Tománek, Center Nr.: 42028
city: Kralupy nad Vltavou
country: Czechia
facility: DIABET HELP s.r.o., Center Nr.: 42058
city: Krnov
country: Czechia
facility: MUDr.Tomáš Edelsberger, Center Nr.: 42007
city: Kromiz
country: Czechia
facility: Jitka Hasalová, Center Nr.: 42010
city: Lede Nad Sázavou
country: Czechia
facility: árka Drinková, Center Nr.: 42038
city: Mladá Boleslav
country: Czechia
facility: Martina Košková, Center Nr.: 42047
city: Nmice Nad Hanou
country: Czechia
facility: Dobromila Vykoupilová, Center Nr.: 42033
city: Nový Jiín
country: Czechia
facility: Karel Churavý, Center Nr.: 42005
city: Nymburk
country: Czechia
facility: árka Kubánková, Center Nr.: 42048
city: Olomouc
country: Czechia
facility: Agentura Science Pro spol. s.r.o., Center Nr.: 42002
city: Olomouc
country: Czechia
facility: Anna Rancová, Center Nr.: 42025
city: Opava
country: Czechia
facility: Josef íný, Center Nr.: 42026
city: Opono
country: Czechia
facility: MUDr.Tomáš Hrdina, Center Nr.: 42015
city: Ostrava Poruba
country: Czechia
facility: Radka Nágelová, Center Nr.: 42020
city: Ostrava
country: Czechia
facility: Dr. Šeptáková, Center Nr.: 42074
city: Ostrava
country: Czechia
facility: Practice Dr. René Turínek, Center Nr.: 42034
city: Ostrava
country: Czechia
facility: MUDr. Eva Raická, Center Nr.: 42024
city: Ostrava
country: Czechia
facility: Jitka Homolová, Center Nr.: 42012
city: Perov
country: Czechia
facility: AIDIN VK s.r.o., Center Nr.: 42017
city: Plze
country: Czechia
facility: Zdenk Jankovec, Center Nr.: 42044
city: Podbrady
country: Czechia
facility: Diabetologická a interní ambulance, Center Nr.: 42064
city: Praha 2
country: Czechia
facility: Practice Dr. Milena Peterková, Center Nr.: 42063
city: Praha 4
country: Czechia
facility: MUDr.Michala Pelikánová s.r.o., Center Nr.: 42055
city: Praha 4
country: Czechia
facility: Markéta Hovorková, Center Nr.: 42042
city: Praha 4
country: Czechia
facility: Jakub Hron, Center Nr.: 42043
city: Praha 5
country: Czechia
facility: Milan Fleka, Center Nr.: 42041
city: Praha 5
country: Czechia
facility: Jií Jón, Center Nr.: 42045
city: Praha 5
country: Czechia
facility: Practice Dr. Lucie Kufová, Center Nr.: 42062
city: Praha 6
country: Czechia
facility: Practice Dr. Ida Reissová, Center Nr.: 42056
city: Praha 9
country: Czechia
facility: Barbora Diepoltová, Center Nr.: 42037
city: Praha
country: Czechia
facility: MUDr. Jana Houdová, Center Nr.: 42068
city: Píbram
country: Czechia
facility: MUDr. Vra Prýmková, Center Nr.: 42070
city: Rumburk
country: Czechia
facility: Practice Dr. Petronela Janeková, Center Nr.: 42065
city: Sokolov
country: Czechia
facility: Practice Dr. Miroslav Lindovský, Center Nr.: 42051
city: Strakonice
country: Czechia
facility: Dana Fialkoviová, Center Nr.: 42040
city: Tebí
country: Czechia
facility: Marek Frydrych, Center Nr.: 42008
city: Tebí
country: Czechia
facility: Marek Frydrych, Center Nr.: 42077
city: Uherské Hradišt
country: Czechia
facility: Diabetologická ambulance s.r.o., Center Nr.: 42076
city: Vlašim
country: Czechia
facility: Dr. Hrmová, Center Nr.: 42073
city: Vrchlabí
country: Czechia
facility: Lubomír Kudlej, Center Nr.: 42050
city: Vsetín
country: Czechia
facility: AdiaMed s.r.o., Center Nr.: 42009
city: Zlín
country: Czechia
facility: EUC Klinika Zlín a.s., Center Nr.: 42075
city: Zlín
country: Czechia
facility: Robin Urbánek, Center Nr.: 42029
city: Budapest
country: Hungary
facility: Bajcsy-Zsilinszky Kórház és Rendelintézet, Center Nr.: 36019
city: Budapest
country: Hungary
facility: Jahn Ferenc Dél-pesti Kórház és Rendelintézet, Center Nr.: 36014
city: Debrecen
country: Hungary
facility: Debreceni Egyetem Klinikai Központ, Kardiológiai Klinika, Center Nr.: 36006
city: Karcag
country: Hungary
facility: Kátai Gábor Kórház, Diabetológia Szakrendelés, Center Nr.: 36007
city: Mátészalka
country: Hungary
facility: Practice Dr. Lelkesi Anita, Center Nr.: 36013
city: Nagyatád
country: Hungary
facility: Nagyatádi Kórház, Center Nr.: 36021
city: Nyíregyháza
country: Hungary
facility: Nyírségi Diabetes Centrum, Center Nr.: 36024
city: Pécs
country: Hungary
facility: Dr. Wagner Zoltán, Center Nr.: 36020
city: Siófok
country: Hungary
facility: Siófoki Kórház Rendelintézet, Center Nr.: 36004
city: Sopron
country: Hungary
facility: Soproni Gyógyközpont, Center Nr.: 36018
city: Biaystok
country: Poland
facility: Gabinet Diabetologiczno- Internistyczny Katarzyna Wasilewska, Center Nr.: 48011
city: Czechowice-Dziedzice
country: Poland
facility: NZOZ DIAMED Sp. z o.o., Center Nr.: 48061
city: Czyca
country: Poland
facility: Prywatny Gabinet Lekarski dr n. med. Joanna Sawer-Szewczyk, Center Nr.: 48055
city: Czyca
country: Poland
facility: Zespó Opieki Zdrowotnej w czycy, Center Nr.: 48054
city: Dzieroniów
country: Poland
facility: NZOZ Sal Med, Center Nr.: 48047
city: Gorlice
country: Poland
facility: Poradnia Diabetologiczna, Center Nr.: 48028
city: Jelenia Góra
country: Poland
facility: Indywidualna Specjalistyczna Praktyka Lekarska Piotr Piskozub Specjalista Diabetolog, Center Nr.: 48042
city: Konin
country: Poland
facility: NZOZ Poradnia Diabetologiczna, Center Nr.: 48038
city: Kraków
country: Poland
facility: Zakad Opieki Medycznej Sanatio; Sp. Z. o.o., Center Nr.: 48030
city: Kutno
country: Poland
facility: Prywatny Gabinet Lekarski Tomasz Wierzykowski, Center Nr.: 48053
city: Kwidzyn
country: Poland
facility: Indywidualna Specjalistyczna Praktyka Lekarska Magorzata Poskoska-Lemaska, Center Nr.: 48035
city: Legnica
country: Poland
facility: Indywidualna Specjalistyczna Praktyka Lekarska Barbara Soróbka, Center Nr.: 48001
city: Lesko
country: Poland
facility: Poradnia Cukrzycowa SP ZOZ w Lesku, Center Nr.: 48024
city: Lubaczów
country: Poland
facility: Lumed Sp. z o.o., Center Nr.: 48032
city: Lubin
country: Poland
facility: DIABETA-CARE Sp.z o.o., Center Nr.: 48008
city: Nako Nad Noteci
country: Poland
facility: Poradnia Diabetologiczna Dr. mudziska, Center Nr.: 48013
city: Nowy Scz
country: Poland
facility: Alfa Specjalistyczne Gabinety Lekarskie Ewa Moroz, Center Nr.: 48007
city: Olenica
country: Poland
facility: Poradnia Diabetologiczna Dr. Adamczyk-Gajda, Center Nr.: 48031
city: Orzesze
country: Poland
facility: MED-ART Sp. z o.o., Center Nr.: 48052
city: Ostrów Wielkopolski
country: Poland
facility: Indywidualna Specjalistyczna Praktyka Lekarska Wiesawa Fischer, Center Nr.: 48020
city: Parczew
country: Poland
facility: Prywatny Gabinet Lekarski azuka, Center Nr.: 48026
city: Stalowa Wola
country: Poland
facility: Powiatowy Szpital Specjalistyczny w Stalowej Woli, Center Nr.: 48056
city: Warszawa
country: Poland
facility: Prywatny Gabinet Lekarski dr n. med. Piotr Gryglas, Center Nr.: 48059
city: Wicbork
country: Poland
facility: Poradnia Diabetologiczna Szpitala Powiatowego w Wicborku, Center Nr.: 48003
city: Woomin
country: Poland
facility: Orodek Praktyka Lekarska Konrad Strzelczyk, Center Nr.: 48012
city: Wyszków
country: Poland
facility: Poradnia Diabetologiczna SPZZOZ w Wyszkowie, Center Nr.: 48067
city: Zabrze
country: Poland
facility: Wojewódzka Poradnia dla Chorych na Cukrzyc, Center Nr.: 48025
city: Zielona Góra
country: Poland
facility: Cardiomed, Center Nr.: 48019
city: Barnaul
country: Russian Federation
facility: Anturium, Center Nr.: 70036
city: Batajsk
country: Russian Federation
facility: Central city hospital, Center Nr.: 70073
city: Chelyabinsk
country: Russian Federation
facility: Chelyabinsk regional clinical hospital, Center Nr.: 70069
city: Ekaterinburg
country: Russian Federation
facility: Limited Liability Company "Uralsky Medical Center", Center Nr.: 70063
city: Ekaterinburg
country: Russian Federation
facility: Scientific and Practical Center of Specialized Types of Medical Care "Uralskij Institute of Cardiology", Center Nr.: 70079
city: Irkutsk
country: Russian Federation
facility: Russian Medical Academy of Continuing Professional Education, Center Nr.: 70058
city: Izhevsk
country: Russian Federation
facility: The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic, Center Nr.: 70037
city: Kazan
country: Russian Federation
facility: Central City Hospital No. 18, Center Nr.: 70051
city: Kemerovo
country: Russian Federation
facility: Kemerovo regional clinical hospital named S.V. Belyaev, Center Nr.: 70008
city: Khabarovsk
country: Russian Federation
facility: City Polyclinic No. 16, Center Nr.: 70067
city: Kirov
country: Russian Federation
facility: Kirov Clinical Hospital No. 7 named after V.I. Yurlova, Center Nr.: 70089
city: Krasnodar
country: Russian Federation
facility: Krai clinical hospital Nr. 1 named after prof. S.V. Ochapovskogo, Center Nr.: 70049
city: Lipetsk
country: Russian Federation
facility: Lipetsk Regional Hospital, Center Nr.: 70046
city: Moscow
country: Russian Federation
facility: SBIH Center for Speech Pathology and Neurorehabilitation MDH, Center Nr.: 70080
city: Moscow
country: Russian Federation
facility: Clinical Hospital No. 85 of trhe Federal Biomedical Agency, Center Nr.: 70042
city: Moscow
country: Russian Federation
facility: City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70043
city: Moscow
country: Russian Federation
facility: City Polyclinic No. 22 of the Department of Healthcare of the Moscow City, Center Nr.: 70045
city: Moscow
country: Russian Federation
facility: City Polyclinic No 107 of the Moscow City Healthcare Department, Center Nr.: 70082
city: Moskau
country: Russian Federation
facility: National Medical Research Center for Endocrinology, Center Nr.: 70025
city: Moskau
country: Russian Federation
facility: Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70032
city: Moskau
country: Russian Federation
facility: Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70041
city: Moskau
country: Russian Federation
facility: Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70081
city: Moskau
country: Russian Federation
facility: Endocrinology Dispensary of the Moscow City Healthcare Department, Center Nr.: 70084
city: Moskau
country: Russian Federation
facility: Vessel Clinic, Center Nr.: 70011
city: Moskau
country: Russian Federation
facility: City Clinical Hospital named after V.V. Veresaeva of the Moscow Department of Health, Center Nr.: 70003
city: Nalchik
country: Russian Federation
facility: City Polyclinic No. 1, Center Nr.: 70074
city: Nizhniy Novgorod
country: Russian Federation
facility: City clinical hospital #12 of Sormovskiy district of Nizhniy Novgorod, Center Nr.: 70018
city: Nizhny Novgorod
country: Russian Federation
facility: Privolzhsky Research Medical University, Center Nr.: 70085
city: Novokuznetsk
country: Russian Federation
facility: Novokuznetsk City Clinical Hospital No. 1, Center Nr.: 70050
city: Novosibirsk
country: Russian Federation
facility: AVICENNA, Center Nr.: 70065
city: Novosibirsk
country: Russian Federation
facility: City Clinical Polyclinic #16, Center Nr.: 70056
city: Novosibirsk
country: Russian Federation
facility: Novosibirsk State Medical University, Center Nr.: 70059
city: Novosibirsk
country: Russian Federation
facility: AVICENNA, Center Nr.: 70064
city: Penza
country: Russian Federation
facility: Penza regional clinical hospital named after N.N. Burdenko, Center Nr.: 70095
city: Perm
country: Russian Federation
facility: Private Clinic Salon Roden, Center Nr.: 70086
city: Perm
country: Russian Federation
facility: City clinical hospital 5, Center Nr.: 70057
city: Perm
country: Russian Federation
facility: City clinical hospital 5, Center Nr.: 70070
city: Rostov-on-Don
country: Russian Federation
facility: City polyclinic #16 of the City Rostov-on-Don, Center Nr.: 70027
city: Saint Petersbug
country: Russian Federation
facility: North-West State Medical University named after II. Mechnikov, Center Nr.: 70053
city: Saint Petersbug
country: Russian Federation
facility: North-West State Medical University named after II. Mechnikov, Center Nr.: 70077
city: Saint Petersburg
country: Russian Federation
facility: Medilux-TM, Center Nr.: 70005
city: Saint Petersburg
country: Russian Federation
facility: City Pokrovskaya Hospital, Center Nr.: 70022
city: Saint-Petersburg
country: Russian Federation
facility: First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70024
city: Saint-Petersburg
country: Russian Federation
facility: First Saint-Petersburg state medical university named after acad. I.P.Pavlov, Center Nr.: 70087
city: Samara
country: Russian Federation
facility: Samara city polyclinic Nr. 9 of Oktyabrskiy district, Center Nr.: 70028
city: Samara
country: Russian Federation
facility: Samara city consulting and diagnostic polyclinic nr. 14, Center Nr.: 70029
city: Saratov
country: Russian Federation
facility: Clinical Hospital of the Saratov city, Center Nr.: 70090
city: Saratov
country: Russian Federation
facility: LLC clinic "Family Doctor", Center Nr.: 70093
city: Saratov
country: Russian Federation
facility: Multifunctional Medical Clinic "Sova", Center Nr.: 70030
city: St. Petersburg
country: Russian Federation
facility: V.A. Almazov National Medical Research Center, Center Nr.: 70071
city: St. Petersburg
country: Russian Federation
facility: AntMed, Center Nr.: 70034
city: St. Petersburg
country: Russian Federation
facility: Dr. Tsiberkin, Center Nr.: 70048
city: St. Petersburg
country: Russian Federation
facility: Zabotlivyi Doktor, Center Nr.: 70016
city: Stavropol
country: Russian Federation
facility: Regional Endocrinological Dispensary, Center Nr.: 70078
city: Tyumen
country: Russian Federation
facility: Tyumen State Medical University, Center Nr.: 70066
city: Ufa
country: Russian Federation
facility: City clinical hospital, Center Nr.: 70019
city: Ulan-Ude
country: Russian Federation
facility: City Polyclinic No.2, Center Nr.: 70062
city: Vladivostok
country: Russian Federation
facility: Limited Liability Company "CENTER", Center Nr.: 70060
city: Vladivostok
country: Russian Federation
facility: Regional Clinical Hospital No. 2, Center Nr.: 70092
city: Vladivostok
country: Russian Federation
facility: Regional Clinical Hospital No. 2, Center Nr.: 70068
city: Volgograd
country: Russian Federation
facility: Volgograd Regional Clinical Hospital No. 3, Center Nr.: 70076
city: Volgograd
country: Russian Federation
facility: Clinical Polyclinic No.28, Center Nr.: 70040
city: Voronezh
country: Russian Federation
facility: Voronezh City Clinical Hospital #11, Center Nr.: 70035
city: Voronezh
country: Russian Federation
facility: State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70017
city: Voronezh
country: Russian Federation
facility: State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70033
city: Voronezh
country: Russian Federation
facility: State budgetary institution "City polyclinic Nr. 4", Center Nr.: 70055
Study officials:
affiliation: Alexey.Medvedchikov@Boehringer-Ingelheim.com
name: Alexey Medvedchikov, +43180105-7896
role: STUDY_CHAIR
References:
citation: Prazny M, Suplotova L, Gumprecht J, Kamenov Z, Fulop T, Medvedchikov A, Rosenzweig D, Aleksandric M. Real-world characteristics, modern antidiabetic treatment patterns, and comorbidities of patients with type 2 diabetes in central and Eastern Europe: retrospective cross-sectional and longitudinal evaluations in the CORDIALLY(R) study. Cardiovasc Diabetol. 2022 Oct 8;21(1):203. doi: 10.1186/s12933-022-01631-4.